IDO1 and melanoma: By using the “patient-matched” cohort of 19 patients, we detected—with exception of patient no. 16—that more than 50% of the IDO+ tumor area was represented by melanoma cells expressing low levels of IDO and that only 10–20% of IDO+ tumor area was represented by immune cells, which showed moderate or high expression intensity (Figure 2B).